Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,738,024 papers from all fields of science
Search
Sign In
Create Free Account
ibritumomab tiuxetan
Known as:
ibritumomab tiuxetan [Chemical/Ingredient]
A monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
14 relations
B-Cell Lymphomas
Drug Allergy
Human B-Lymphocyte Antigen CD20, human
Lactation
Expand
Narrower (4)
IDEC-Y2B8
Murine Monoclonal Antibody 2B8
Zevalin
yttrium-90-ibritumomab tiuxetan
Broader (1)
Monoclonal Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
Ibritumomab tiuxetan for non-Hodgkin’s lymphoma
Patrick B Johnston
,
Cara Bondly
,
Ivana N M Micallef
Expert Review of Anticancer Therapy
2006
Corpus ID: 31918616
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B…
Expand
Review
2005
Review
2005
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
G. Wiseman
,
T. Witzig
Cancer Biotherapy and Radiopharmaceuticals
2005
Corpus ID: 34702739
AIM Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B…
Expand
2005
2005
Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
A. Gokhale
,
J. Mayadev
,
B. Pohlman
,
R. Macklis
International Journal of Radiation Oncology…
2005
Corpus ID: 25352987
2004
2004
Yttrium‐90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome
A. Tsimberidou
,
J. Murray
,
S. O'brien
,
W. Wierda
,
M. Keating
Cancer
2004
Corpus ID: 42932233
90Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with…
Expand
Review
2004
Review
2004
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
S. Spies
Seminars in nuclear medicine
2004
Corpus ID: 410472
Yttrium 90 ibritumomab tiuxetan consists of the murine monoclonal antibody ibritumomab securely bound to the second-generation…
Expand
2004
2004
Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan.
J. Siegel
,
B. Zimmerman
,
K. Kodimer
,
M. Dell
,
W. Simon
Journal of Nuclear Medicine
2004
Corpus ID: 38855010
UNLABELLED This investigation examined the accuracy of dose calibrator activity measurement of the beta-emitting…
Expand
Review
2004
Review
2004
Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
J. Winter
Clinical Lymphoma
2004
Corpus ID: 7631269
Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar…
Expand
Review
2003
Review
2003
Radioimmunotherapy for NHL: Experience of 90Y-Ibritumomab Tiuxetan in Clinical Practice
A. Hagenbeek
Leukemia and Lymphoma
2003
Corpus ID: 22815697
Radioimmunotherapy (RIT) is a novel treatment modality that combines the benefits of radiotherapy and immunotherapy, enabling…
Expand
Review
2002
Review
2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
L. Gordon
,
T. Witzig
,
+10 authors
A. Grillo‐López
Seminars in Oncology
2002
Corpus ID: 25663190
The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New…
Expand
Review
2002
Review
2002
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
M. Juweid
Journal of Nuclear Medicine
2002
Corpus ID: 1249149
Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin's lymphoma (NHL). Recent clinical trials have clearly…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE